Internal Medicine, Hematology & Oncology · Minneapolis, MN
NPI
1336223866
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
7
Medicare group memberships
Hospitals
3
Hospital affiliations
420 Delaware St SE, Mmc 480
Minneapolis, MN, 55455
Phone (612) 625-1104
Groups this clinician bills Medicare through
Medicare paid, 2024
$15K
186 services
Medicare patients, 2024
114
Average age 62
Drug cost, 2024
$1.1M
516 prescriptions
Company payments, 2025
$70K
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark T Reding was code 99215 (office e&m - established), 47 times for 35 patients. In total Mark T Reding billed 186 services in 15 codes, and Medicare paid $15K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-01-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 47 | 35 | $99.57 | $4,680 |
| 99214 Office E&M - Established | Office | 20 | 14 | $82.09 | $1,642 |
| 99205 Office E&M - New | Facility | 15 | 15 | $117.64 | $1,765 |
| 99214 Office E&M - Established | Facility | 15 | 12 | $69.93 | $1,049 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 15 | 11 | $12.54 | $188 |
By year: 2022 $18K for 204 services; 2023 $13K for 143 services; 2024 $15K for 186 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark T Reding prescribed most often to Medicare patients was Xarelto (Rivaroxaban), with 57 prescriptions and refills. In total Mark T Reding wrote 516 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | 57 | 135 | 17 | $72K |
| Oxycodone Hcl Generic | 56 | 56 | Under 11 | $1,402 |
| Warfarin Sodium Generic | 56 | 123 | 14 | $969 |
| Eliquis Apixaban | 49 | 68 | Under 11 | $37K |
| Retacrit Epoetin Alfa-Epbx | 33 | 33 | Under 11 | $20K |
| Oxycontin Oxycodone Hcl | 30 | 30 | Under 11 | $125K |
| Fondaparinux Sodium Generic | 29 | 33 | Under 11 | $52K |
| Jantoven Warfarin Sodium | 23 | 38 | Under 11 | $494 |
| Tranexamic Acid Generic | 18 | 18 | Under 11 | $3,292 |
| Celecoxib Generic | 18 | 18 | Under 11 | $256 |
| Promacta Eltrombopag Olamine | 14 | 22 | Under 11 | $283K |
| Hydroxyurea Generic | 13 | 32 | Under 11 | $531 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 13 | 13 | Under 11 | $179 |
| Oxbryta Voxelotor | 13 | 13 | Under 11 | $160K |
| Imbruvica Ibrutinib | 11 | 11 | Under 11 | $23K |
Brand drugs: 237 claims; generic drugs: 279 claims; opioid claims: 101.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark T Reding $70K ($70K in general payments such as food, travel and fees) from 9 companies. The largest payer was Sanofi US Services Inc. with $20K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.